Advisors Asset Management Inc. Buys 1,504 Shares of Humana Inc (HUM)

Advisors Asset Management Inc. grew its stake in Humana Inc (NYSE:HUM) by 26.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,209 shares of the insurance provider’s stock after acquiring an additional 1,504 shares during the quarter. Advisors Asset Management Inc.’s holdings in Humana were worth $2,146,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sun Life Financial INC lifted its position in shares of Humana by 120.7% in the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after acquiring an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in Humana by 2,984.6% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock worth $119,000 after buying an additional 388 shares during the period. NuWave Investment Management LLC purchased a new position in Humana during the second quarter worth about $198,000. Main Street Research LLC purchased a new position in Humana during the second quarter worth about $201,000. Finally, Jaffetilchin Investment Partners LLC purchased a new position in Humana during the second quarter worth about $205,000. Institutional investors and hedge funds own 92.99% of the company’s stock.

Shares of NYSE:HUM opened at $318.25 on Monday. The stock has a market cap of $43.84 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 1.58 and a beta of 0.97. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana Inc has a 12 month low of $231.90 and a 12 month high of $341.30.



Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.79 by $0.17. The company had revenue of $14.26 billion during the quarter, compared to analyst estimates of $14.16 billion. Humana had a return on equity of 17.43% and a net margin of 2.48%. During the same period in the prior year, the firm posted $3.49 earnings per share. Research analysts predict that Humana Inc will post 14.18 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, October 26th. Shareholders of record on Friday, September 28th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $2.00 annualized dividend and a yield of 0.63%. Humana’s dividend payout ratio is presently 17.08%.

In other news, SVP Cynthia H. Zipperle sold 4,886 shares of the stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $321.89, for a total value of $1,572,754.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Insiders have sold 40,284 shares of company stock valued at $13,147,715 over the last 90 days. 0.60% of the stock is currently owned by insiders.

HUM has been the topic of several recent analyst reports. Argus increased their target price on Humana to $375.00 and gave the stock a “buy” rating in a research report on Tuesday, September 4th. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a research report on Wednesday, July 4th. Piper Jaffray Companies reiterated a “buy” rating and set a $355.00 target price on shares of Humana in a research report on Thursday, August 2nd. Bank of America increased their target price on Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Finally, Jefferies Financial Group increased their target price on Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Humana has an average rating of “Buy” and an average price target of $339.79.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: Stock Split

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply